A phase 2 trial to evaluate the efficacy and safety of WZTL-002, a third-generation anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (ENABLE-2).
Authors: Aine Hurley, Philip George, Giulia Giunti, Brittany Lavender, Amy Holmes, Clinton Lewis, Robert Weinkove